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against aldosterone-induced glomerular injury
J Ma1, A Weisberg2, JP Griffin2, DE Vaughan3, AB Fogo4 and NJ Brown2
1Division of Pediatric Nephrology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA;
2Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA;
3Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA and
4Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
This study tests the hypothesis that plasminogen activator
inhibitor-1 (PAI-1) contributes to aldosterone-induced renal
and cardiac injury. The effects of 12-week aldosterone
(2.8 lg/day)/salt (1% drinking water) versus vehicle/salt on
renal and cardiac histology and mRNA expression were
determined in wild-type (WT) and PAI-1 deficient (PAI-1(/))
mice. Systolic blood pressure was similar in aldosterone-
infused WT and PAI-1(/) mice until 12 weeks, when it was
significantly higher in the WT mice. At 12 weeks, urine
volume, sodium excretion, and sodium/potassium ratio were
similarly increased in the two aldosterone-infused groups.
In contrast, urine albumin excretion was greater in
aldosterone-infused WT mice (mean7s.d.: 699.07873.0 lg/
24 h) compared to vehicle-infused WT (23.679.0 lg/24 h,
P¼ 0.003) or aldosterone-infused PAI-1(/) mice
(131.67110.6 lg/24 h, P¼ 0.007). Aldosterone increased
glomerular area to a greater extent in WT (46517577 versus
32787488 lm2/glomerulus in vehicle-infused WT, Po0.001)
than in PAI-1(/) mice (37137705 lm2/glomerulus, P¼ 0.001
versus aldosterone-infused WT), with corresponding
mesangial expansion. Renal collagen content was also
increased in aldosterone-infused WT versus PAI-1(/) mice. In
WT mice, aldosterone increased renal mRNA expression of
PAI-1, collagen I, collagen III, osteopontin, fibronectin,
monocyte chemoattractant protein-1 (MCP-1), and F4/80 (all
Po0.05), but not transforming growth factor beta (TGF-b). In
PAI-1(/) mice, aldosterone increased renal expression of
collagen I, osteopontin, fibronectin, and MCP-1, and tended
to increase collagen III. Renal osteopontin expression was
diminished in aldosterone-treated PAI-1(/) compared to
aldosterone-treated WT mice (P¼ 0.05). Aldosterone induced
cardiac hypertrophy but not fibrosis in WT and PAI-1(/)
mice. PAI-1 contributes to aldosterone-induced glomerular
injury.
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The last several years have seen a paradigm shift in our
understanding of how aldosterone contributes to cardio-
vascular and renal injury. Whereas it was once thought that
aldosterone acts primarily as a circulating hormone involved
in the regulation of sodium excretion through mineralocor-
ticoid receptor (MR)-dependent mechanisms, studies now
provide evidence for local, extra-adrenal production of
aldosterone, as well as for extra-renal actions of aldosterone.1
Aldosterone contributes to inflammatory and fibrotic effects
that were previously attributed solely to angiotensin (Ang)
II.2–4 In clinical studies, MR antagonism has been shown to
decrease mortality in patients with congestive heart failure,5,6
to improve endothelial function,7 to reduce circulating
markers of collagen turnover,8 and to decrease microalbu-
minuria.9–13
In rats, studies have consistently demonstrated that
aldosterone causes cardiac hypertrophy and fibrosis through
an MR-dependent pathway in the setting of high salt
intake.14–17 Similarly, aldosterone causes inflammation and
fibrosis and glomerular injury in the kidney in hypertensive
rats.2,17–19 In these models, aldosterone induces cellular
infiltration and the expression of inflammatory markers
such as cyclooxygenase (COX)-2, ED-1 (rat monocyte/
macrophage marker), interleukins, and osteopontin prior to
the development of fibrosis.4,18 However, the mechanism(s)
involved in the progression from inflammation to fibrosis has
not been delineated.
One possible mechanism through which aldosterone may
promote the development of fibrosis is through induction of
plasminogen activator inhibitor-1 (PAI-1) expression. Aldo-
sterone induces PAI-1 expression in vascular smooth muscle
cells and endothelial cells,20 cardiomyocytes, and mono-
cytes,21 whereas MR antagonism decreases PAI-1 expression
in the heart of Ang II/NG-nitro-L-arginine methyl ester
(L-NAME)-treated mice22 and in the rat kidney following
radiation injury or streptozotocin treatment.23,24 PAI-1, a
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principal inhibitor of plasminogen activators, can promote
fibrosis by preventing the activation of matrix metallopro-
teinases (MMPs) and the degradation of extracellular matrix
(ECM) by plasminogen activators and plasmin.25 Studies
using PAI-1-deficient or -overexpressing animals have
implicated PAI-1 in the pathogenesis of bleomycin-induced
pulmonary fibrosis,26 perivascular fibrosis following nitric
oxide synthase inhibition,27 and renal fibrosis following
unilateral ureteral obstruction.28
The present study tests the hypothesis that PAI-1
contributes to aldosterone-induced cardiac and renal injury.
To do this, we determined the effect of aldosterone/salt
administration in uninephrectomized wild-type (WT) and
PAI-1-deficient animals.
RESULTS
Hemodynamic effects
Figure 1 shows systolic blood pressure (SBP) in each of the
four treatment groups. SBP did not change significantly over
the 12 weeks of the study in any of the treatment groups and
was not significantly different among the study groups over
the entire period of the study (mean SBP 108.379.0,
116.979.0, 113.279.0, and 112.679.0 mmHg in vehicle-
infused WT, aldosterone-infused WT, vehicle-infused PAI-
1(/), and aldosterone-infused PAI-1(/) mice, respectively,
P¼ 0.160) However, SBP was significantly higher at 12 weeks
in aldosterone-infused WT compared to either vehicle-
infused WT (P¼ 0.025) or aldosterone-infused PAI-1(/)
mice (P¼ 0.007).
Renal function
As illustrated in Table 1, plasma aldosterone concentrations
were significantly and similarly increased in either group of
aldosterone-infused mice compared to vehicle-infused mice.
Glucose concentrations were similar among the treatment
groups at all time points. Baseline urine volume, sodium or
potassium excretion, and albumin excretion were similar
among treatment groups, while baseline urine sodium/
potassium ratio was mildly but significantly increased in
PAI-1(/) mice. At 12 weeks, water consumption (not
shown) and urine volume, as well as urine sodium excretion
and the urine sodium/potassium ratio were significantly
increased in the two aldosterone-infused groups. There was
no difference in any of these parameters between aldosterone-
infused WT and PAI-1(/) mice. In contrast, urine protein
excretion, as measured by either the albumin/creatinine ratio
or 24-h albumin excretion, was significantly increased in
aldosterone-infused WT mice compared to either vehicle-
infused mice or to aldosterone-infused PAI-1(/) mice.
Renal histology
Body weights were similar at 12 weeks among all four
treatment groups (Table 2). The kidney/body weight ratio
was significantly increased in aldosterone-infused WT and
PAI-1(/) mice compared to vehicle-infused mice and this
effect was significantly greater in the aldosterone-infused WT
mice (Po0.05). The kidneys of both aldosterone-infused WT
and PAI-1(/) mice demonstrated marked collecting duct
dilatation, associated with focal hyperplasia and hypertrophy,
a lesion not found in vehicle-treated mice (Figure 2).
Compared to the kidneys of vehicle-infused mice, the
kidneys of aldosterone-infused mice were characterized
by glomerular hypertrophy. However, glomerular area
(P¼ 0.001, Table 2) and mesangial area (P¼ 0.035) were
increased to a significantly greater extent in kidneys from
aldosterone-infused WT mice compared to aldosterone-
infused PAI-1(/) mice. Glomerular collagen IV content
also tended to be increased in aldosterone-infused WT mice
compared to aldosterone-infused PAI-1(/) mice (P¼ 0.058,
Table 2). Aldosterone tended to induce interstitial fibrosis
(P¼ 0.071 for treatment effect) but did not cause perivas-
cular fibrosis in WT or PAI-1(/) mice. Total renal collagen
content was increased in aldosterone-infused WT mice
compared to aldosterone-infused PAI-1(/) (P¼ 0.039) or
vehicle-infused WT (P¼ 0.024) mice. Renal plasmin activity
was increased in vehicle-infused PAI-1(/) compared to
vehicle-infused WT mice, but was similar in aldosterone-
infused PAI-1(/) and WT mice (Table 2). However, MMP-2
activity was increased in vehicle-infused PAI-1(/) and
increased further in aldosterone-infused PAI-1(/) mice,
such that MMP-2 activity was higher in aldosterone-infused
PAI-1(/) mice compared to WT mice.
F4/80-positive cells were detected in the renal interstitium
but not in glomeruli (Table 2, Figure 3a–d). Compared to the
kidneys of vehicle-infused WT mice, the kidneys of
aldosterone-infused WT and PAI-1(/) mice showed sig-
nificantly increased number of F4/80-positive cells, especially
in areas of interstitial fibrosis and surrounding interlobular
arteries and glomeruli. There was no significant difference in
macrophage staining of aldosterone-infused PAI-1(/) mice
compared to vehicle-infused PAI-1(/) mice. Interstitial
fibrosis was increased in aldosterone-infused compared to
vehicle-infused PAI-1(/) mice, but not compared to WT
mice.
0 2 4 6 8 10 12
70
80
90
100
110
120
130
140
WT vehicle (N=8)
WT aldosterone (N=9)
PAI-1 (−/−) vehicle (N=11)
PAI-1 (−/−) aldosterone (N=10)
*†
Time (weeks)
SB
P 
(m
mH
g)
Figure 1 | Effect of vehicle and aldosterone infusion on systolic
blood pressure (SBP) in wild-type (WT) and plasminogen
activator inhibitor-1 (PAI-1 (/)) mice. *P¼ 0.025 versus vehicle-
infused wild-type, wP¼ 0.007 versus aldosterone-infused PAI-1(/).
Kidney International (2006) 69, 1064–1072 1065
J Ma et al.: Aldosterone, PAI-1, and glomerular injury o r i g i n a l a r t i c l e
Cardiac function and cardiac and aortic histology
Heart weight/body weight was significantly and similarly
increased in the two aldosterone-infused groups (Table 3).
Likewise, aldosterone induced comparable aortic medial
hypertrophy in the WT and PAI-1(/) mice. On the other
hand, aldosterone increased some measures of left ventricular
hypertrophy (LVFT at autopsy and interventricular septum in
systole (IVSs) on echocardiography) to a greater extent in
Table 1 | Metabolic and renal functional parameters in WT and PAI-1(/) mice
WT PAI-1(/)
Vehicle (N=8) Aldosterone (N=9) Vehicle (N=11) Aldosterone (N=10)
Aldosterone (pg/ml)
Week 12 163.5789.5 462.67365.7*,w 166.27141.4 600.47455.7*,z
Glucose (mg/dl)
Week 0 161.5712.0 157.7714.6 160.6715.2 154.6725.2
Week 12 133.8725.7 119.9722.6 150.6723.2 129.4727.6
Urine volume (ml)
Week 0 1.370.5 1.370.6 1.570.5 1.170.7
Week 12 4.071.1 21.9710.1y,8 4.772.9 21.8717.8y,8
Urine Na (mEq/day)
Week 0 250796 237785 243796 1907120
Week 12 10957341 337171551z,w 15517624 409173354*,8
Urine K (mEq/day)
Week 0 6327191 5117182 5117229 3847279
Week 12 6547133 8637561 5687290 5827380
Urine Na/K ratio
Week 0 0.3970.07 0.4770.08 0.5270.14z 0.5970.16*
Week 12 1.6770.29 4.2071.61y,z 2.0370.34 7.6278.20z,z
Urine albumin/creatinine ratio (mg/mg)
Week 0 10.377.7 13.5713.9 9.573.0 12.276.1
Week 12 22.977.4 167.97190.2*,8 21.979.7 35.8714.3#
Urinary albumin excretion (mg/24 h)
Week 0 7.873.5 10.878.6 7.872.5 5.673.2
Week 12 23.679.0 699.07873.0*,8 23.7714.7 131.67110.6**
PAI-1, plasminogen activator inhibitor-1; WT, wild type.
*Pp0.005 versus vehicle-infused wild-type mice, wPo0.05 versus vehicle-infused PAI-1(/) mice, zPp0.005 versus vehicle-infused PAI-1(/) mice, yPp0.001 versus vehicle-
infused wild-type mice, 8Po0.001 versus vehicle-infused PAI-1(/) mice, zPo0.05 versus vehicle-infused wild-type mice, #Po0.005 versus aldosterone-infused wild-type mice,
**Po0.01 versus aldosterone-infused wild-type mice.
Table 2 | Renal morphology and histology in WT and PAI-1(/) mice
WT PAI-1(/)
Vehicle (N=8) Aldosterone (N=9) Vehicle (N=11) Aldosterone (N=10)
Body weight (g) 26.571.0 28.572.4 27.171.7 27.572.3
Kidney weight/body weight (mg/g) 9.6670.55 13.3971.17*,w 8.6670.60 12.1472.16*,w,z
Glomerular area (mm2/glomerulus) 32787488 46527577*,w 29537513 37137705y,8
Glomerular mesangial area (points/glomerulus) 7.6671.41 10.5072.67z,w 6.2270.73 8.0271.72
Glomerular collagen IV area (mm2) 7127166 13357359*,w 7507242 10797319y,z
Renal interstitial fibrosis score 0.1370.35 0.6771.00 0.0970.30 0.7870.83y
Macrophage infiltration score 070 1.4471.01*,y 0.5470.82 1.2270.67#
Renal collagen content (mg/g) 3.471.0 6.373.2z 4.270.5 3.571.4z
Glomerular PSmad2 staining score 1.470.9 2.771.3 1.870.8 2.371.3
Tubular PSmad2 staining score 3.271.6 2.670.5 2.671.1 4.571.3z,y
Renal plasmin activity (mU/mg) 0.2170.16 0.6270.31 0.6370.69* 0.5670.23
MMP-2 activity 0.2870.10 0.7570.17* 0.7070.16* 1.0370.31*,z,y
MMP-9 activity 3.0070.82 3.8771.01 4.9971.79# 4.0770.99
MMP, matrix metalloproteinases; PAI-1, plasminogen activator inhibitor-1; WT, wild type.
*Po0.001 versus vehicle-infused wild-type mice, wPp0.001 versus vehicle-infused PAI-1(/), zPo0.05 versus aldosterone-infused wild-type mice, yPo0.05 versus vehicle-
infused PAI-1(/), 8P=0.001 versus aldosterone-infused wild-type, zPo0.05 versus vehicle-infused wild-type, #Po0.005 versus vehicle-infused wild-type.
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WT mice than in PAI-1(/) mice. Likewise, aldosterone
infusion was associated with an increase in estimated left
ventricular mass (LVMd)/body weight measured by echo-
cardiography in WT, but not in PAI-1(/) mice. Fractional
shortening was significantly greater in either vehicle- and
aldosterone-infused PAI-1(/) mice compared to WT mice.
Aldosterone did not induce significant cardiac fibrosis
(Table 3, P¼ 0.324), F4/80 staining (data not shown), or
aortic medial fibrosis in WT or PAI-1(/) mice.
Renal gene expression
In WT mice, aldosterone increased the renal mRNA
expression of PAI-1, collagen I, collagen III, osteopontin,
fibronectin, monocyte chemoattractant protein-1 (MCP-1),
and F4/80, but not transforming growth factor beta (TGF-b)
compared to vehicle infusion (Figure 4). As expected, there
was no significant PAI-1 expression in PAI-1(/) mice. In
PAI-1(/) mice, aldosterone induced increased renal mRNA
expression of collagen I, osteopontin, fibronectin, and MCP-1
and tended to increase expression of collagen III (P¼ 0.078),
but not F4/80. Renal osteopontin expression was significantly
decreased in aldosterone-infused PAI-1(/) animals com-
pared to aldosterone-infused WT mice. Osteopontin expres-
sion correlated significantly with glomerular area
(Spearman’s correlation coefficient 0.534, P¼ 0.002) and
the urine albumin/creatinine ratio (correlation coefficient
0.810, Po0.001). By in situ hybridization, osteopontin
mRNA signal localized to the tubules and to capillary loops,
consistent with endothelial cells, and to podocytes within
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Figure 2 | Renal histological changes in wild-type and PAI-1(/)
mice given aldosterone and 1% NaCl after uninephrectomy.
Glomeruli were enlarged with mesangial expansion in kidneys from
(b) aldosterone-infused wild-type mice versus (a) those from wild-
type mice infused with vehicle and (d) those from PAI-1(/) mice
infused with aldosterone. (c) Comparison between the vehicle- and
(d) aldosterone-infused PAI-1(/) kidneys suggests that PAI-1
deficiency protected against aldosterone-induced damage in this
model. Aldosterone infusion also caused remarkable dilatation,
hypertrophy, and hyperplasia of renal collecting tubules in both
WT and PAI-1(/) kidneys with occasional calcium deposits (e).
Bar¼ 100 mm (periodic acid-Schiff).
a b
c
e f
g h
d
Figure 3 | Renal macrophage infiltration in wild-type and PAI-1(/)
mice given aldosterone and 1% NaCl after uninephrectomy.
There was scattered infiltration of macrophages in the renal
interstitium in both vehicle-infused (a) wild-type and (c) PAI-1(/)
mice. F4/80-positive macrophages were increased in the interstitium
of kidneys from (b) wild-type and (d) PAI-1 (/) mice infused with
aldosterone. Bar¼ 100mm (antibody to F4/80). (e) Osteopontin mRNA
signal (blue–purple) was detected in the collecting tubules (arrow) of
aldosterone-treated WT mice. (f) In glomeruli of aldosterone-infused
WT mice, osteopontin mRNA signal was detected on podocytes
(black arrows) stained with WT-1 (brown) and capillary loop,
consistent with endothelial cells (yellow arrow). Immunohistochemistry
for PSmad2 (brown) showed increased staining in the (g) glomeruli
of aldosterone-infused WT mice and (h) the tubules of aldosterone-
infused PAI-1(/) mice.
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glomeruli (Figure 3e and f). TGF-b expression was
significantly increased in the kidney of both vehicle- and
aldosterone-infused PAI-1(/) mice compared to vehicle-
infused WT mice. Phospho-Smad2 (PSmad2) staining tended
to be increased in the glomeruli of aldosterone-infused WT
mice, whereas tubular PSmad2 tended to be increased in
aldosterone-infused PAI-1(/) mice (Table 2 and Figure 3g
and h).
Cardiac gene expression
Figure 5 shows the effect of aldosterone treatment on cardiac
gene expression in WT and PAI-1(/) mice. Although
aldosterone tended to increase cardiac PAI-1 expression in
Table 3 | Cardiac and aortic morphology and echocardiographic measurements in WT and PAI-1(/) mice
WT PAI-1(/)
Vehicle (N=8) Aldosterone (N=9) Vehicle (N=11) Aldosterone (N=10)
Heart weight/body weight (mg/g) 4.9470.26 5.9870.76*,w 5.0370.52 6.7171.62z,y
Left ventricular free wall (mm) 543.47226.9 790.07250.08,z 555.4785.7 678.77121.4
Fibrosis score 0.8170.37 1.0670.53 0.8670.32 1.1770.56
PSmad2-positive cells/HPF 78.3717.5 74.7721.2 80.6716.4 98.1743.5
Aortic media (mm) 48.0778.18 62.65712.418,y 45.6877.45 64.70712.088,y
Aortic adventia (mm) 30.878.7 36.4715.0 33.877.2 42.9712.1
Echocardiography
IVSd (cm) 0.09770.004 0.10970.014 0.10070.008 0.10170.009
LVIDd (cm) 0.28070.026 0.30670.040 0.27170.024 0.29770.041
LVPWd (cm) 0.09270.009 0.10670.009*,w 0.09370.011 0.10070.016
IVSs (cm) 0.17570.014 0.19370.020* 0.18070.011 0.17370.017#
LVIDs (cm) 0.14470.021 0.15770.026z 0.12370.012 0.14870.035w
LVPWs (cm) 0.11970.015 0.13370.018 0.12170.019 0.13770.030
FS (%) 48.675.6 48.972.7 54.571.88,** 50.775.1w
HR (b.p.m.) 733732 723716 713718 684780
LVMd (g) 0.08670.012 0.12170.0318,z 0.08570.017 0.10470.030
LVMd/BW (mg/g) 3.270.5 4.270.9*,z 3.070.6 3.871.2w
BW, body weight; d, diastolic; FS, fractional shortening; HR, heart rate; HPF, high power field; IVS, interventricular septum; LV, left ventricular; LVID, LV internal dimension;
LVM, LV mass; LVPW, LV posterior wall; PAI-1, plasminogen activator inhibitor-1; s, systolic; WT, wild type.
*Po0.05 versus vehicle-infused wild-type mice, wPo0.05 versus vehicle-infused PAI-1(/) mice, zPo0.001 versus vehicle-infused wild-type, yPp0.001 versus vehicle-infused
PAI-1(/), 8Po0.01 versus vehicle-infused wild-type, zPo0.01 versus vehicle-infused PAI-1(/), #Po0.05 versus aldosterone-infused wild-type mice, **Po0.005 versus
aldosterone-infused wild-type mice.
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Figure 4 | Effect of aldosterone treatment on renal gene expres-
sion in wild-type (WT) and plasminogen activator inhibitor-1
(PAI-1) (/) mice. N was 5 or more per group. *Pp0.05 versus
vehicle-infused WT, wPp0.001 versus vehicle-infused PAI-1(/),
zPp0.008 versus vehicle-infused WT, yPo0.005 versus aldosterone-
infused WT, 8Po0.001 versus vehicle-infused WT, zPo0.05 versus
aldosterone-infused WT, #Po0.05 versus vehicle-infused PAI-1(/).
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Figure 5 | Effect of aldosterone treatment on cardiac gene
expression in wild-type (WT) and plasminogen activator inhibi-
tor-1 (PAI-1) (/) mice. N was 5 or more per group. *Po0.001 versus
vehicle-infused WT mice, wPo0.001 versus aldosterone-infused WT
mice, zPo0.01 versus vehicle-infused WT mice, yPo0.05 versus
aldosterone-infused WT mice, 8Po0.01 versus vehicle-infused PAI-1(/)
mice, zPo0.01 versus aldosterone-infused WT mice, #Po0.05 versus
vehicle-infused PAI-1(/) mice, **Po0.05 versus either vehicle-
infused groups, wwPo0.05 versus vehicle-infused WT.
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WT mice, this effect was not significant (P¼ 0.093).
Aldosterone increased cardiac osteopontin expression in
WT or PAI-1(/) mice (P¼ 0.019 for an overall effect of
aldosterone) but, in contrast to the kidney, cardiac osteo-
pontin expression was similar in aldosterone-infused WT and
PAI-1(/) mice. Moreover, aldosterone induced cardiac
expression of collagen I and III and TGF-b in PAI-1(/)
mice but not in WT mice. However, the number of PSmad2-
positive cells in the heart was similar among all of the
treatment groups. Because there were no morphological or
histological differences between the aortas of aldosterone-
infused WT and PAI-1(/) mice, we did not determine aortic
gene expression.
DISCUSSION
Aldosterone causes glomerular injury in animal models,
whereas MR antagonism reduces proteinuria and glomerular
sclerosis in hypertensive rats.2,17–19 MR antagonism also
reduces urinary albumin excretion in patients with hyper-
tensive or diabetic nephropathy.9–13 At the same time, PAI-1
has been implicated in animal models of interstitial fibrosis
and glomerulosclerosis, including ureteral obstruction-in-
duced interstitial fibrosis, crescentic glomerulonephritis, anti-
Thy-1 glomerulonephritis, and diabetic nephropathy.28–32
Experimental data indicating that aldosterone induces PAI-1
expression in vitro,20,21 and that MR antagonism reduces
glomerular PAI-1 expression and sclerosis in vivo,23,24
suggested the hypothesis that aldosterone induces glomerular
injury, in part, by enhancing PAI-1 expression. The present
study addresses this hypothesis and indicates that genetic
PAI-1 deficiency protects against aldosterone-induced
glomerular injury, as measured histologically by glomerular
and mesangial expansion and functionally by albumin
excretion.
In both WT and PAI-1(/) mice, aldosterone/salt
increased urine volume, sodium excretion, and urine
sodium-to-potassium ratio, consistent with increased con-
sumption of saline, as well as with the ‘aldosterone-escape’
phenomenon whereby the kidney overcomes aldosterone-
mediated tubular NaCl reabsorption in the setting of normo-
or hypervolemia, most likely through a decrease in the
thiazide-sensitive NaCl cotransporter of the distal convoluted
tubule.33 Similarly, aldosterone caused renal tubular dilata-
tion in both WT and PAI-1(/) mice, described previously in
transgenic mice overexpressing the human MR.34 PAI-1
deficiency also did not affect aldosterone-induced interstitial
inflammation. In contrast, PAI-1 deficiency attenuated
aldosterone-induced glomerular injury despite similar aldos-
terone concentrations, potassium and sodium excretion, and
glucose concentrations in WT and PAI-1(/) mice.
PAI-1 deficiency could protect against glomerular injury
via decreased ECM formation or increased degradation. As in
unilateral ureteral observation-induced interstitial fibrosis,28
PAI-1 deficiency was not associated with enhanced renal
plasmin activity during aldosterone treatment. Likewise,
aldosterone induced statistically similar increases in renal
collagen and fibronectin expression in WT and PAI-1(/)
mice. Taken together with the finding that total renal collagen
content and intraglomerular collagen IV were decreased in
aldosterone-infused PAI-1(/) mice compared to WT mice,
the data are compatible with enhanced ECM degradation in
the aldosterone-treated PAI-1(/) mice via a plasmin-
independent pathway, possibly via increased activity of
MMP-2.
It is not possible to exclude a blood pressure-dependent
protective effect of PAI-1 deficiency on aldosterone-induced
renal injury with certainty. On the one hand, SBP was similar
among the groups until the end of the study and the degree
of cardiac and aortic medial hypertrophy was similar in the
aldosterone-infused WT and PAI-1(/) mice at autopsy. On
the other hand, SBP was higher in the aldosterone-infused
WT mice relative to the PAI-1(/) mice at the last week of
the study and some echocardiographic measures of left
ventricular hypertrophy imply a greater pressor stimulus
in the aldosterone-infused WT mice compared to the
aldosterone-infused PAI-1(/) mice. However, the fact that
blood pressure diverged only late in the study suggests that
this difference in blood pressure was a consequence of, rather
than a cause of, glomerular injury.
As reported previously in Sprague–Dawley rats,18 aldo-
sterone significantly increased renal expression of the
inflammatory marker genes osteopontin, MCP-1, and F4/
80. Importantly, in PAI-1(/) mice, attenuation of glomer-
ular injury was associated with decreased osteopontin
expression. Further studies are needed to investigate the
interaction between PAI-1 and osteopontin expression in the
kidney. However, binding to integrin ligands such as collagen
I and fibronectin induces osteopontin expression in osteo-
blastic cells.35 If adhesion to integrins similarly stimulates
podocyte osteopontin expression, PAI-1 deficiency could
alter osteopontin expression by enhancing degradation of
collagen and fibronectin.
Significantly, aldosterone/salt treatment did not increase
TGF-b expression in the kidney. This is compatible with
prior data in b6(/) mice indicating that aldosterone can
induce renal PAI-1 expression and fibrosis through a TGF-b-
independent pathway.36 Surprisingly, however, renal mRNA
expression of TGF-b was increased in PAI-1(/) versus WT
mice in the presence or absence of aldosterone. Based on
PSmad2 staining, active TGF-b was also increased in the
tubules of aldosterone/salt-treated PAI-1(/) mice. This may
account for increased interstitial fibrosis in these mice
compared to vehicle-treated PAI-1(/) mice. While it is
known that TGF-b increases PAI-1 expression,37 that plasmin
activates TGF-b,38 and that PAI-1 deficiency can lead to
activation of TGF-b,39 to the best of our knowledge this is the
first observation of increased TGF-b expression associated
with PAI-1 deficiency. Rather, other groups have reported
decreased TGF-b expression in injured PAI-1(/) mice;28
however, a recent study in cultured mesangial cells suggests
that the effect of PAI-1 on TGF-b expression may depend on
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interactions with urokinase plasminogen activator and its
receptor.32
Aldosterone/salt induced cardiac TGF-b expression in
both WT and PAI-1(/) mice; increased TGF-b expression
could have contributed to the development of hypertrophy.40
However, aldosterone/salt did not induce cardiac fibrosis in
the current study, contrary to the profibrotic effect of
aldosterone/salt observed in rat models.14–16 Similar findings
in other studies in mice22,41 suggest that there may be species
differences in susceptibility to Ang II or aldosterone/salt-
induced cardiac fibrosis. In this regard, the minimal pressor
response to aldosterone observed in the present study
contrasts the 30–50 mmHg increase in blood pressure
typically reported during chronic aldosterone/salt treatment
in rats, despite comparable aldosterone doses on a per weight
basis.14,42 Given evidence that aldosterone/salt induces
cardiac fibrosis in part through upregulation of the AT1
receptor,43,44 differences in susceptibility to fibrosis in rats
and mice could reflect species differences in Ang II receptor
regulation.45
Despite the lack of cardiac fibrosis in aldosterone-treated
mice, PAI-1 deficiency interacted synergistically with aldo-
sterone to induce cardiac expression of collagens I and III.
These findings are compatible with the data of Oestreicher
et al.,22 who reported that PAI-1 deficiency increased
inflammation induced by 2-week hypertensive treatment
with Ang II and the nitric oxide synthase inhibitor L-NAME.
Similarly, pharmacological PAI-1 inhibition and genetic PAI-1
deficiency promote Ang II-induced cardiac fibrosis.46 The
divergent effects of PAI-1 deficiency on the expression of
profibrotic genes in the heart and the kidney may reflect
different roles for PAI-1 in these two organs.47 While PAI-1
promotes ECM accumulation by inhibiting MMP activation
and retarding ECM turnover (as in the glomerulus), PAI-1
can retard inflammation and fibrosis by impeding urokinase
plasminogen activator or plasmin-mediated activation or
release of latent growth factors. If during PAI-1 deficiency,
urokinase plasminogen activator or plasmin-mediated acti-
vation of growth factors exceeds degradation of ECM, fibrosis
will result. Consistent with this hypothesis, excess cardiac
fibrosis has been reported in aged PAI-1-deficient mice and
in mice overexpressing macrophage urokinase plasminogen
activator.48
In summary, aldosterone/salt induced glomerular hyper-
trophy and injury, as well as cardiac and aortic hypertrophy
in this mouse model. PAI-1 deficiency protected against both
aldosterone/salt-induced glomerular hypertrophy and injury,
but not against macrophage infiltration, interstitial fibrosis,
or activation of tubular TGF-b. PAI-1 deficiency did not
affect cardiac and aortic hypertrophy and increased the
cardiac expression of profibrotic genes. These findings have
important implications for the treatment of aldosterone-
dependent renal disease, and suggest site-specific differential
interactions of aldosterone/salt and PAI-1. MR antagonism
reduces urinary albumin excretion in patients with hyper-
tensive or diabetic nephropathy.9–13 Therapeutic strategies to
reduce PAI-1 production or activity may be of value in
preventing aldosterone-induced glomerular injury but may
not reduce interstitial fibrosis.
MATERIALS AND METHODS
Animals
Adult male PAI-1(/) mice which had been backcrossed for eight
generations on a C57BL/6J background (Jackson Laboratory, Bar
Harbor, ME, USA) and C57BL/6J WT mice were studied. All animals
were housed in a pathogen-free environment with a 12-h light/dark
cycle and had free access to standard mouse chow and tap water
until the initiation of the study. All animal procedures were
approved by the Vanderbilt University Institutional Animal Care
and Use Committee.
Protocol
After a 2–3-week training period for blood pressure measurements,
8- to 10-week-old mice were uninephrectomized under anesthesia
with pentobarbital (50 mg/kg, i.p.) at week 0. At the same time, WT
and PAI-1(/) mice were randomized to subcutaneous implanta-
tion of an osmotic mini-pump (Alzet model 2004, Alza Co., Palo
Alto, CA, USA) containing either 0.467 mg/ml D-aldosterone (Sigma,
St Louis, MO, USA) or vehicle (3.6% v:v dimethyl sulfoxide).
Beginning at week 0, all mice were given drinking water containing
1% NaCl. At 4 and 8 weeks, pumps were explanted and a new
pump was implanted under pentobarbital anesthesia. Thus,
aldosterone-treated mice were given 2.8 mg aldosterone per day for
12 weeks.
SBP was measured using tail-cuff impedance plethysmography
(BP-2000 Blood Pressure Analysis System, Visitech Systems, Apex,
NC, USA) in trained unanesthetized mice prewarmed for 5–10 min
at 371C every 2 weeks. At week 0 and week 12, 24 h urine was
collected in metabolic cages (Nalgene Co., Rochester, NY, USA).
Because PAI-1 deficiency can decrease serum glucose concentra-
tions,49 30 ml of blood was obtained from the saphenous vein for
measurement of blood glucose at 0, 2, 4, 8, and 12 weeks. Mice were
killed at week 12 by cervical dislocation. The renal artery was
clamped and blood was drawn from the heart. The heart, the aorta,
and the kidney were then harvested and the heart and kidney were
weighed. The base of the heart, the first 2 mm of descending aorta,
and coronal sections of the kidney were fixed in 4% buffered
paraformaldehyde overnight and then processed and embedded in
paraffin for histological evaluation. The remainder of the heart,
aorta, and kidney were snap-frozen in liquid nitrogen for mRNA
analysis.
Biochemical measurements
Urine sodium and potassium and serum potassium were measured
by flame photometry. Urinary albumin, creatinine, and albumin/
creatinine ratio were determined using a Bayer DCA2000 system
(Elkhart, IN, USA). Blood glucose was measured using a
HemoCues (A¨ngelholm, Sweden) B-Glucose Analyzer. Aldosterone
was measured using a commercially available radioimmunoassay
(MP Biomedicals, Irvine, CA, USA). Hydroxyproline, measured by
high-pressure liquid chromatography (HPLC) was used to assess the
total collagen content in renal tissue from at least four mice per
group. Renal plasmin activity was measured by chromogenic assay
with a plasmin-specific chromogenic substrate, Chromozym PL
(Boehringer Mannheim, Indianapolis, IN, USA),28 and activities of
MMP-2 and MMP-9 were examined by zymography on gelatin gels
as described in detail online.50
1070 Kidney International (2006) 69, 1064–1072
o r i g i n a l a r t i c l e J Ma et al.: Aldosterone, PAI-1, and glomerular injury
Echocardiography
Transthoracic echocardiography was performed in conscious mice at
week 11 using a 15-MHz transducer (Sonos 5500 system, Agilent,
Andover, MA, USA).51 Left ventricular wall thickness and chamber
dimensions were determined from M-mode tracings, and the
fractional shortening (FS%) and estimated left ventricular mass
(LVM) were calculated as previously described. Heart rate (HR) was
determined from the cardiac cycles recorded on the M-mode tracing
using at least 10 consecutive beats.
Histology
All histological evaluation and morphometric analysis were per-
formed in a blinded fashion. Four micrometer sections of paraffin-
embedded kidney tissue were stained with periodic acid-Schiff.
Glomerular morphometric analysis was performed using a  40
objective on at least 30 consecutive glomeruli and averaged for each
animal. Glomerular area was measured by using KS300 Software
(Kontron Electronic GmbH, Eching, Germany). A point-counting
method was applied to assess glomerular mesangial volume. In total,
50 points were assessed for each glomerulus and the number of points
falling exclusively on the mesangium was counted. Glomerular
collagen content was semiquantified using KS300 Software on
sections stained for collagen IV as described online.
Paraffin-embedded sections (4 mm) of the heart and aorta were
stained with Masson’s trichrome. Free wall thickness of the left
ventricle (LVFT) was measured under the  10 objective by using
KS300 software. The thicknesses of media and adventitia of the aorta
were measured on cross-sections with the  20 objective. Cardiac
fibrosis was graded according to the presence or absence of
subendocardial fibrosis (0.5), mild intra-cardiac fibrosis (1.0),
moderate multi-focal intra-cardiac fibrosis (1.5), or multi-focal
intra-cardiac fibrosis with perivascular extension (2). Aortic medial
fibrosis was graded as absent (0), minimal focal (0.5), mild multi-
focal (1), and moderate multi-focal (2).
Quantitative real-time PCR
Total RNA was extracted using RNAWiz (Ambion, Austin, TX, USA)
and RNeasy Midi Kit (Qiagen, Valencia, CA, USA). Reverse
transcription was performed using TaqMan Reverse Transcription
Kit (Applied Biosystems, Branchburg, NJ, USA). Primers and
conditions are available online. Experimental cycle threshold (Ct)
values were normalized to b-actin measured on the same plate, and
fold differences in gene expression were determined using the 2DDCt
method.52
Immunohistochemistry and in situ hybridization
Detailed methods for immunohistochemistry against F4/80 and
PSmad2 appear online. F4/80-positive cells in the interstitium of the
kidney were assessed by a macrophage infiltration score, with 0
indicatingo20 positive cells in any high power field (HPF,  40), 1
indicating X20 but o50 positive cells in any HPF, 2 indicating
patchy moderate infiltrate with X50 up to 100 positive cells in any
HPF, and 3 indicating focal, patchy, severe infiltrate with X100
positive cells in any HPF. PSmad2 staining was assessed in  40
HPFs and scored as 1–6 denoting 40 and p50, 450 and p100,
4100 and p150, 4150 and p200, 4200 and p250, 4250
positive nuclei per HPF for tubules, while scored as 1– 5 denoting
40 and p5, 45 and p10, 410 and p15, 415 and p20, 420
positive nuclei per glomerulus for each animal. An average score was
then calculated for each animal.
Statistical analysis
Results are expressed as mean7s.d. in the text and tables and
means7s.e.m. in figures. Repeated measures analysis of variance
was used to assess the effect of treatment on SBP. One-way analysis
of variance, followed by post hoc testing using least significant
difference, was used to evaluate differences in continuous variables,
such as albumin excretion, among groups. Results were confirmed
using non-parametric tests. Histological injury scores were com-
pared using w2 testing. All tests were two-tailed and a Po0.05 was
considered statistically significant.
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